Approval criteria for Non-preferred inhalers and/or regimens
Customize your policy alerts
Sign up for allcareadvantage Policy 017.2 alerts
Get alerted when Policy 017.2 changes without checking for updates manually.
Monitor payer policy activity
Defines prior authorization and approval criteria for coverage of non-preferred inhaler products and inhaler regimens for members with asthma, reactive airways disease (RAD), or COPD who are established on a reliever (e.g., albuterol). Applies to AllCare Advantage members.
No material clinical or coverage changes in this revision.
Coverage Criteria for Non-Preferred Inhalers and Regimens
There are no additional explicit exclusions beyond failure to meet the policy’s sequential approval criteria. Requests will be denied when required steps in the decision flow are not met, including lack of documentation of the qualifying diagnosis (asthma, reactive airways disease, or COPD) or lack of documentation of a reliever medication for acute symptoms (e.g., albuterol).
The requested non-preferred drug and/or regimen must be FDA‑approved for the submitted and/or comorbid diagnoses or be supported by clinical guidelines or appropriate compendia to meet approval criteria. If the agent/regimen is not FDA‑approved for the indication and lacks guideline/compendia support, the request will be denied as not meeting criteria.
Coding and Quantity Limits
| No codes listed |
Provider Actions, Documentation, and Denial Triggers
Prior authorization required for non-preferred inhalers/regimens
Prior authorization is required for requests for non-preferred inhaler products or inhaler regimens; coverage decisions follow the policy’s stepwise review of diagnosis, reliever availability, preferred status, trials of preferred agents with good compliance, consideration of preferred combination alternatives, and FDA approval or supporting guideline/compendia evidence.
Step therapy: trial of preferred formulary inhaler(s) required
Members must trial preferred formulary inhaler(s) or regimen(s) and demonstrate good compliance before approval of non-preferred agents; prescribers should consider switching to a preferred combination inhaler when available to reduce inhaler burden and cost.
Required documentation: diagnosis and reliever medication
Provide documentation that supports the diagnosis of asthma, reactive airways disease (RAD), or COPD and documentation that the member has a reliever medication for acute symptoms (e.g., albuterol).
- Clinical record or diagnostic documentation confirming asthma, RAD, or COPD
- Medication list or prescription showing a reliever (e.g., albuterol) on the current regimen
Document trials and compliance when preferred options were used
If the request is for a non-preferred product, document a trial of preferred formulary inhaler(s)/regimen(s) with good compliance and note consideration of preferred combination inhalers as alternatives; if preferred options were tried and denied by the prescriber, document the clinical reason.
- Dates and duration of trial(s) of preferred inhaler(s)/regimen(s)
- Evidence of good adherence during the trial(s)
- If prescriber declines a suggested preferred combination, a statement of clinical rationale for not switching
Denial triggers: missing diagnosis, no reliever, or lacking FDA/guideline support
Requests may be denied if there is no documentation of the required diagnosis (asthma, RAD, or COPD) or if there is no documentation that the member has a reliever medication for acute symptoms (e.g., albuterol); requests for drugs/regimens that are not FDA‑approved for the submitted/comorbid diagnoses and not supported by guidelines/compendia will also be denied.
- Missing or absent diagnostic documentation → deny
- No evidence of reliever medication on the member’s regimen → deny
- Requested drug/regimen not FDA‑approved for the diagnosis and not supported by clinical guidelines/appropriate compendia → deny
Definitions and Examples
Background
Chronic airflow limitation conditions such as asthma and COPD are commonly managed with inhaled maintenance therapies plus an as‑needed reliever medication for acute symptoms (example: albuterol). Treatment complexity and the number of separate inhalers can reduce adherence; where possible, preferred combination inhalers may improve adherence, reduce inhaler burden, and lower cost. AllCare Advantage requires documentation of diagnosis and reliever availability and prefers trials of formulary preferred inhalers with good compliance prior to approving non-preferred inhalers or regimens.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.